Skip to main content

CORRECTION article

Front. Immunol., 15 June 2023
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1235273

Corrigendum: Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients

This article is a correction to:

  1. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients

    1. Read original article
Xinhua Chen&#x;Xinhua Chen1†Huimin Zhang&#x;Huimin Zhang2†Minghao Wang&#x;Minghao Wang1†Hao LiuHao Liu1Yanfeng HuYanfeng Hu1Tian LinTian Lin1Hao ChenHao Chen1Mingli ZhaoMingli Zhao1Tao ChenTao Chen1Guoxin Li*Guoxin Li1*Jiang Yu*Jiang Yu1*Liying Zhao*Liying Zhao1*
  • 1Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, China
  • 2The First Clinical Medical School, Southern Medical University, Guangzhou, China

A Corrigendum on
Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients

By Chen X, Zhang H, Wang M, Liu H, Hu Y, Lin T, Chen H, Zhao M, Chen T, Li G, Yu J and Zhao L (2022) Front. Immunol. 13:783695. doi: 10.3389/fimmu.2022.783695

In the published article, there was an error in the author list, and author Guoxin Li was listed erroneously, and should be denoted as a corresponding author. The corrected author list appears below.

Xinhua Chen1†, Huimin Zhang2†, Minghao Wang1†, Hao Liu1, Yanfeng Hu1, Tian Lin1, Hao Chen1, Mingli Zhao1, Tao Chen1, Guoxin Li1*, Jiang Yu1*, Liying Zhao1*

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: gastric cancer, PD-L1, CPS, Ki-67, biopsy, pathology

Citation: Chen X, Zhang H, Wang M, Liu H, Hu Y, Lin T, Chen H, Zhao M, Chen T, Li G, Yu J and Zhao L (2023) Corrigendum: Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients. Front. Immunol. 14:1235273. doi: 10.3389/fimmu.2023.1235273

Received: 06 June 2023; Accepted: 07 June 2023;
Published: 15 June 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Chen, Zhang, Wang, Liu, Hu, Lin, Chen, Zhao, Chen, Li, Yu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Liying Zhao, zlyblue11@163.com; Jiang Yu, balbc@163.com; balbcyujiang@163.com; Guoxin Li, gzliguoxin@163.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.